Shuta Ohara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shuta Ohara has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Kenichi Suda
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, JAPAN
36 shared publications - Tetsuya Mitsudomi
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, JAPAN
31 shared publications - Yasuhiro Tsutani
Division of Thoracic Surgery, Department of Surgery, Faculty of Medicine, Kindai University, Osaka, Japan
31 shared publications - Akira Hamada
Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Osaka-Sayama, JAPAN
29 shared publications - Hidenori Sato
Kanazawa University
23 shared publications - Kouya Shiraishi
Division of Genome Biology National Cancer Center Research Institute Tokyo Japan
23 shared publications
Latest Publications
- Open Access
Circulating Tumor DNA-Based Molecular Residual Disease in Early-Stage Non-Small-Cell Lung Cancer: Biology, Assays, and the Path Toward MRD-Guided Care
Complete surgical resection remains the cornerstone of curative therapy for early-stage non-small-cell lung cancer (NSCLC), yet a substantial proportion of patients relapse despite a macroscopically complete operation and negative conventional staging. This residual risk reflects micrometastatic disease that is below the resolution of computed tomography and that current clinicopathologic risk factors only coarsely predict. Circulating tumor DNA (ctDNA) provides a direct, blood-based readout of this molecular residual disease (MRD), its detection after definitive treatment is among the strongest known predictors of recurrence, and ctDNA frequently rises months before radiographic progression. In this narrative review, based on a literature search closed on 12 September 2026, we synthesize the foundational and translational literature underpinning ctDNA-MRD in resected NSCLC. We outline the biology of ctDNA shedding and metastatic dissemination established by serial-sampling and phylogenetic studies; the prognostic performance of landmark and longitudinal MRD, tabulated quantitatively across the major cohorts, meta-analyses and trial-nested analyses; the perioperative kinetics that dictate when sampling is informative; the analytical design of tumor-informed versus tumor-agnostic assays and the determinants of their sensitivity; and the biological and technical sources of false-negative and false-positive results, of which clonal hematopoiesis and low-shedding histologies are the most consequential. We then position MRD within the contemporary perioperative treatment landscape—adjuvant targeted therapy and immunotherapy, and neoadjuvant and perioperative chemoimmunotherapy—and review the emerging, still-investigational paradigm of MRD-guided escalation and de-escalation, including the early termination of the MRD-selected MERMAID trials. We conclude with the analytical, evidentiary and implementation barriers—and the current positions of guideline bodies and regulators—that separate a powerful prognostic biomarker from a validated predictive tool, and we set out the trial-design requirements needed to close that gap.
Open AccessCirculating Tumor DNA-Based Molecular Residual Disease in Early-Stage Non-Small-Cell Lung Cancer: Biology, Assays, and the Path Toward MRD-Guided Care
Complete surgical resection remains the cornerstone of curative therapy for early-stage non-small-cell lung cancer (NSCLC), yet a substantial proportion of patients relapse despite a macroscopically complete operation and negative conventional staging. This residual risk reflects micrometastatic disease that is below the resolution of computed tomography and that current clinicopathologic risk factors only coarsely predict. Circulating tumor DNA (ctDNA) provides a direct, blood-based readout of this molecular residual disease (MRD), its detection after definitive treatment is among the strongest known predictors of recurrence, and ctDNA frequently rises months before radiographic progression. In this narrative review, based on a literature search closed on 12 September 2026, we synthesize the foundational and translational literature underpinning ctDNA-MRD in resected NSCLC. We outline the biology of ctDNA shedding and metastatic dissemination established by serial-sampling and phylogenetic studies; the prognostic performance of landmark and longitudinal MRD, tabulated quantitatively across the major cohorts, meta-analyses and trial-nested analyses; the perioperative kinetics that dictate when sampling is informative; the analytical design of tumor-informed versus tumor-agnostic assays and the determinants of their sensitivity; and the biological and technical sources of false-negative and false-positive results, of which clonal hematopoiesis and low-shedding histologies are the most consequential. We then position MRD within the contemporary perioperative treatment landscape—adjuvant targeted therapy and immunotherapy, and neoadjuvant and perioperative chemoimmunotherapy—and review the emerging, still-investigational paradigm of MRD-guided escalation and de-escalation, including the early termination of the MRD-selected MERMAID trials. We conclude with the analytical, evidentiary and implementation barriers—and the current positions of guideline bodies and regulators—that separate a powerful prognostic biomarker from a validated predictive tool, and we set out the trial-design requirements needed to close that gap.
- Open Access
- 26 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109344
Lack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study
- 26 February 2026
- Published by Elsevier in Lung Cancer
- Vol. 214, 109344
Open AccessLack of impact of antibiotics and proton pump inhibitors on the efficacy of preoperative chemoimmunotherapy in locally advanced non-small cell lung cancer: A multicenter retrospective study
- 7 January 2026
- Published by Elsevier in Lung Cancer
- Vol. 212, 108908
Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)
- 7 January 2026
- Published by Elsevier in Lung Cancer
- Vol. 212, 108908
Survival outcomes of patients with uncommon EGFR mutations in surgically resected lung adenocarcinoma: A multi-institutional real-world database study (CReGYT-01 EGFR study)
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S1. Study One-hundred sixty eight genes which were differently expressed between these two groups were further narrowed down by NMF analysis. For the details of genes included in R1/R2/R3 and N1/N2/N3, please see Supplementary Table S1.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
The study concept and the identification of candidate genes. A, The analytic flow of this study including cohort 1 (a discovery set of matched patients who experienced disease recurrence and patients who did not for >5 years), cohort 2a (a testing set of a real-world cohort), cohort 2b (additional real-world cohort), and TCGA database (a validation set). B, OPLS-DA analysis revealed that gene expression status differed between patients who experienced disease recurrence (red) and those who did not for >5 years (blue). C, A volcano plot to identify differentially expressed genes between patients who experienced disease recurrence and those who did not for >5 years. Of the genes that meet the selection criteria, upregulated or downregulated genes in the recurrence group are shown in red or blue, respectively. Fc, fold change.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S9. Prognostic implications of BMP6 and OLFM1 (stage-specific analysis).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Recurrence-free survival of patients in Cohort 2a in the high expression group and low expression group for each gene (A, BMP6; B, KCNK3; C, NFASC; D, OLFM1; E, PEG3; and F, TNXB).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Recurrence-free survival of patients in Cohort 2a in the high expression group and low expression group for each gene (A, BMP6; B, KCNK3; C, NFASC; D, OLFM1; E, PEG3; and F, TNXB).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S7. Concordance rates (A) between identified 6 genes and p-values (B).
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Figure S7. Concordance rates (A) between identified 6 genes and p-values (B).
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
RFS of patients categorized by BMP6 and OLFM1 expression status. A and B, RFS in cohort 2a, a real-world cohort of patients with pStage I nonsquamous NSCLC whose tumors were analyzed using PolyA sequencing. C and D, RFS in the cohort of patients with EGFR mutations extracted from cohort 1 and cohort 2. H&H, high and high indicates higher expression of both BMP6 and OLFM1; H&L, high and low indicates higher expression for either of the BMP6 and OLFM1 and lower expression for the other; L&L, low and low indicates lower expression of both BMP6 and OLFM1.
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
RFS of patients categorized by BMP6 and OLFM1 expression status. A and B, RFS in cohort 2a, a real-world cohort of patients with pStage I nonsquamous NSCLC whose tumors were analyzed using PolyA sequencing. C and D, RFS in the cohort of patients with EGFR mutations extracted from cohort 1 and cohort 2. H&H, high and high indicates higher expression of both BMP6 and OLFM1; H&L, high and low indicates higher expression for either of the BMP6 and OLFM1 and lower expression for the other; L&L, low and low indicates lower expression of both BMP6 and OLFM1.
- Open Access
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S4. Multivariable analysis of 6 genes for RFS in the Cohort 2a (N = 125)
- 18 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor Appearance
Table S4. Multivariable analysis of 6 genes for RFS in the Cohort 2a (N = 125)